Related Experiment Video
Updated: Aug 24, 2026

04:36
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial
R M Stone1, J De Angelo, I Galinsky
1Dana-Farber Cancer Institute, Boston, MA, USA.
Annals of Hematology
|May 6, 2004
Abstract
No abstract available in PubMed .
